Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

BME-Dependent Cell Invasion Assay

October 6, 2010 8:49 am | Product Releases | Comments

Combining research on factors affecting BME-dependent cell invasion assay performance with the advantages of offering the assay in a format where the BME is already coated on the invasion plate, the 96 well CultreCoat optimized BME cell invasion assay was designed.


Thermal Cyclers

October 6, 2010 8:29 am | Product Releases | Comments

Thermo Fisher Scientific Inc. has introduced the Piko and Arktik Thermal Cyclers. These two Thermo Fisher Scientific PCR instruments meet the needs of a broad range of researchers, for applications covering individual PCRs through to high throughput projects.


Laboratory Information Management System

October 6, 2010 8:18 am | Product Releases | Comments

Two Fold Software’s easy-to-use Qualoupe LIMS solution has been tailored to support the requirements of commercial contract research laboratories.


Nuevolution Joins Drug Discovery Group

October 6, 2010 8:02 am | News | Comments

A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.


Cisbio Partners With Blue Sky

October 6, 2010 7:59 am | News | Comments

Cisbio Bioassays, member of IBA Group and global provider of HTRF (homogenous time resolved fluorescence) technology and services to facilitate new drug discovery, announces the signing of a partnership with Blue Sky BioProducts.


Serotonin Uses Special Pathway

October 6, 2010 7:44 am | News | Comments

Scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances.


HDL Controlling Drug Target Found

October 6, 2010 7:40 am | News | Comments

Thanks to a discovery by a Saint Louis University researcher, scientists have identified an important microRNA that may allow us to better control cholesterol levels in blood.


Benicar Superior to Cozaar in New Study

October 6, 2010 7:33 am | News | Comments

Patients treated with Benicar in BeniVICTOR study experienced significantly greater blood pressure reductions and higher goal attainment rates than patients treated with Cozaar after 8 weeks.


FDA Approves Additional Veletri Uses

October 6, 2010 7:28 am | News | Comments

Actelion Ltd announced that the U.S. Food and Drug Administration has approved additional in-use conditions for administration of Veletri, an improved formulation of epoprostenol.


GE Launches Heart-Muscle Tox Test

October 6, 2010 7:19 am | News | Comments

Geron says GE Healthcare is now selling a human cardiomyocyte-based toxicology screening product the companies developed together.


Three Win Nobel Prize Key Chemical Tool

October 6, 2010 7:13 am | by Karl Ritter | News | Comments

An American and two Japanese scientists won the Nobel Prize in chemistry for finding new ways to bond carbon atoms together, methods now widely used to make medicines and even slimmed-down computer screens.


FDA Warns Gilead on Manufacturing Issues

October 6, 2010 7:09 am | by Matthew Perrone | News | Comments

The Food and Drug Administration posted a warning letter on its website, outlining more than a half-dozen quality-control problems uncovered by inspectors on a routine visit to Gilead's San Dimas, Calif., facility.


Novartis Cancelling Two Drugs

October 6, 2010 7:06 am | News | Comments

Novartis AG said it will take a charge of $590 million during the third quarter as it discontinues development of a potential hepatitis C drug and an antifungal product.


Judge Approves $600M Botox Settlement

October 6, 2010 6:58 am | by Greg Bluestein | News | Comments

A federal investigation into Allergan Inc.'s misleading marketing of its wrinkle-smoothing Botox medication is over after a judge in Georgia approved the pharmaceutical firm's decision to pay $600 million and plead guilty to misbranding the product.


Pfizer May Sell Capsugel

October 6, 2010 6:54 am | News | Comments

Pfizer Inc. said it is reviewing its strategic alternatives for its Capsugel business unit, which makes hard capsules used to deliver medication.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.